CIBC Private Wealth Group
BNTC icon

CIBC Private Wealth Group’s Benitec Biopharma BNTC Stock Holding History

CIBC Private Wealth Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12
Closed -$10K – 1971
2018
Q1 		$10K Hold
12
– – ﹤0.01% 1526
2017
Q4 		$9K Buy
+12
New +$8.39K ﹤0.01% 1567

Other funds holding BNTC

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CIBC Private Wealth Group's BNTC Position: Q2 2018 in Review

CIBC Private Wealth Group sold out of Benitec Biopharma (BNTC) in Q2 2018, closing a stake of 12 shares — an estimated $10K sold.

CIBC Private Wealth Group first reported a position in BNTC in Q4 2017 and held it in 2 quarters. The position peaked at $10K in Q1 2018. 6 funds tracked by Wall St. Rank hold BNTC as of Q2 2018.

  • CIBC Private Wealth Group reported no remaining Benitec Biopharma position as of Q2 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 12 Benitec Biopharma shares in Q2 2018, an estimated $10K.
  • CIBC Private Wealth Group first reported a position in Benitec Biopharma in Q4 2017 and held it in 2 quarters.
  • CIBC Private Wealth Group's Benitec Biopharma position peaked at $10K in Q1 2018.
  • 6 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2018.

Based on CIBC Private Wealth Group's 13F filing for Q2 2018, filed 2 Aug 2018.